苯酰胺,N-[4-氯-3-(三氟甲基)苯基]- | 17765-66-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苯酰胺,N-[4-氯-3-(三氟甲基)苯基]-
• 英文名称: N-(4-chloro-3-(trifluoromethyl)phenyl)benzamide
• 英文别名: 4-Benzamino-1-chlor-2-trifluormethyl-benzol；4'-Chlor-3'-(trifluormethyl)-benzanilid；N-[4-chloro-3-(trifluoromethyl)phenyl]benzamide
• CAS: 17765-66-1
• 化学式: C₁₄H₉ClF₃NO
• 分子量: 299.68
• InChiKey: KRNWWEIKCXPQDA-UHFFFAOYSA-N

物化性质

• 沸点：
  288.9±40.0 °C(Predicted)
• 密度：
  1.401±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-(Hydroxyamino)-5,6,7,8-tetrahydronaphthalen-2-ol 、 苯酰胺,N-[4-氯-3-(三氟甲基)苯基]- 以 二甲基亚砜 为溶剂， 反应 16.0h， 以60%的产率得到1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(7-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)urea
  参考文献：
  名称：

  Naphthol derivatives as TRPV1 inhibitors for the treatment of urinary incontinence

  摘要：

  We have identified naphthol derivatives as inhibitors of the vanilloid receptor TRPV1 by high throughput screening. The initial lead showed high clearance in rats and has been optimized by enhancing the acidity of the phenol group. Compound 6b has reduced clearance, improved potency and is active in rat cystometry models of urinary incontinence after intravenous administration. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.013
• 作为产物：
  描述：

  5-溴-2-氯三氟甲苯 、 苯甲酰胺 在 potassium phosphate 、 methanesulfonato(2-dicyclohexylphosphino-3,6-dimethoxy-2',4',6'-tri-i-propyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) 作用下， 以 1,4-二氧六环 、 水 为溶剂， 150.0 ℃ 、1.38 MPa 条件下， 反应 0.25h， 以68%的产率得到苯酰胺,N-[4-氯-3-(三氟甲基)苯基]-
  参考文献：
  名称：

  Modular Continuous Flow Synthesis of Imatinib and Analogues

  摘要：

  A modular continuous flow synthesis of imatinib and analogues is reported. Structural y diverse imatinib analogues are rapidly generated using three readily available building blocks via a flow hydration/chemoselective C-N coupling sequence. The newly developed continuous flow hydration and amidation modules each exhibit a broad scope with good to excellent yields. Overall, the method described does not require solvent switches, in-line purifications, or packed-bed apparatuses due to the judicious manipulation of flow setups and solvent mixtures.

  DOI：

  10.1021/acs.orglett.9b02259

文献信息

• [EN] ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE<br/>[FR] DERIVES D'AMIDE D'ACIDE ANTHRANILIQUE ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：NOVARTIS AG

  公开号：WO2004052884A1

  公开（公告）日：2004-06-24

  The present invention relates to new anthranilic acid amide derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof - alone or in combination with one or more other pharmaceutically active compounds.

  本发明涉及新的蒽酰胺衍生物，其制备方法，其在用于治疗人体或动物体的过程中的应用，以及其单独使用或与一个或多个其他药用活性化合物结合使用的用途。
• [EN] N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS<br/>[FR] DERIVES DE N-ARYL(THIO)ANTHRANILIQUE ACIDE AMIDE, LEUR PREPARATION ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE DU RECEPTEUR VEGF
  申请人：NOVARTIS AG

  公开号：WO2000027820A1

  公开（公告）日：2000-05-18

  Described are compounds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10-(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y = SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

  本文描述了式(I)的化合物，其中W是O或S；X是NR8；Y是CR9R10-(CH2)n，其中R9和R10独立地是氢或低级烷基，n是0至3的整数；或者Y是SO2；R1是芳基；R2是一个含有一个或多个环氮原子的单环或双环杂环基团，但R2不能代表2-苯甲酰亚胺基，且在Y = SO2的情况下不能代表2,1,3-苯并噻二唑-4-基；R3、R4、R5和R6中的任何一个，除了氢之外，都是取代基；R7和R8独立地是氢或低级烷基；或其N-氧化物或药学上可接受的盐，用于制备用于治疗对VEGF受体酪氨酸激酶活性抑制有反应的肿瘤疾病的制药产品。式(I)的化合物可用于治疗肿瘤疾病、视网膜病变和年龄相关性黄斑变性等疾病。
• Substituted 2-anilinobenzoxazoles
  申请人：Eli Lilly and Company

  公开号：US04275210A1

  公开（公告）日：1981-06-23

  Compositions comprising certain 2-(substituted anilino)benzoxazoles, such as 2-[4-bromo-3-(trifluoromethyl)-anilino]benzoxazole, and methods for using same as immunosuppressive agents, antifertility agents, for the prophylaxis of Marek's disease in chickens and as herbicides.

  本发明涉及包含特定的2-（取代的苯胺基）苯并咪唑的复合物，例如2-[4-溴-3-(三氟甲基)-苯胺基]苯并咪唑，并且使用它们作为免疫抑制剂、抗生育剂、用于预防鸡马立克病和除草剂的方法。
• Substituted 2-anilinobenzoxazoles used as immunosuppressive agents
  申请人：Eli Lilly and Company

  公开号：US04088770A1

  公开（公告）日：1978-05-09

  Compositions comprising certain 2-(substituted anilino)benzoxazoles, such as 2-[4-bromo-3-(trifluoromethyl)anilino]benzoxazole, and methods for using same as immunosuppressive agents, antifertility agents, for the prophylaxis of Marek's disease in chickens and as herbicides.

  本发明涉及含有某些2-(取代基苯胺基)苯并噁唑的组合物，例如2-[4-溴-3-(三氟甲基)苯胺基]苯并噁唑，并将其用作免疫抑制剂、避孕剂、预防鸡马立克病的药物和除草剂的方法。
• N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS
  申请人：Novartis AG

  公开号：EP1129075A1

  公开（公告）日：2001-09-05